Healius Limited (ASX:HLS): What FY26 Pathology Earnings Reveal About Its Operating Priorities

Healius Limited (ASX:HLS) provides tests used by clinicians to diagnose and monitor medical conditions. Its FY26 annual report identifies 72 laboratories and 1,883 collection centres within a network of 1,955 sites across Australia. The footprint covers large cities as well as regional communities, and …

Aditi Sarkar | 02 November 2026

PYC Therapeutics (ASX:PYC): Clinical Programmes, RNA Delivery and 2026 Milestones

PYC Therapeutics Limited (ASX:PYC) focuses on diseases associated with mutations in individual genes. Its approach uses peptide-linked oligonucleotide technology designed to alter the production of specific proteins. The company identifies programmes in ocular, central nervous system and renal disorders. These are clinical and development …

Aditi Sarkar | 02 November 2026

PolyNovo (ASX:PNV): FY26 Revenue, NovoSorb Sales and Manufacturing Plans

PolyNovo Limited (ASX:PNV) sells NovoSorb Biodegradable Temporising Matrix, known as BTM, and NovoSorb MTX for medical applications involving tissue repair. The company operates directly in several markets, including Australia and the United States, and uses distributors in other territories. Its FY26 reporting distinguishes United …

Aditi Sarkar | 02 November 2026

Australian Clinical Labs (ASX:ACL): FY26 Pathology Revenue, Margins and FY27 Guidance

Australian Clinical Labs Limited (ASX:ACL) operates pathology laboratories and specimen collection centres serving primary care and hospital settings. Services cover chemical pathology, haematology, microbiology, molecular diagnostics, antenatal screening and other diagnostic categories. The company’s official profile describes a national network of laboratories and approved …

Aditi Sarkar | 02 November 2026

How Did Integral Diagnostics (ASX:IDX) Perform in FY26 After Its Imaging Network Expansion?

In its 25 August 2026 results, Integral Diagnostics (ASX:IDX) reported revenue and other income of AUD 788.7 million for the year ended 30 June 2026, an increase of 25.6% year on year. Operating EBITDA reached AUD 164.8 million, up 30.3%, with the operating EBITDAMarginat …

Aditi Sarkar | 02 November 2026

Telix Pharmaceuticals (ASX:TLX): What Do 2026 Revenue Growth and Pipeline Investment Show?

For the six months ended 30 June 2026, Telix Pharmaceuticals (ASX:TLX) recorded revenue of USD 477 million, up 22% year on year. Group grossMarginwas 55%, while adjusted EBITDA was USD 52 million.Research and Developmentexpenditure reached USD 124 million. Profit after tax of USD 38 …

Aditi Sarkar | 02 November 2026

Why Did Monash IVF Group (ASX:MVF) Report Lower FY26 Earnings Despite Cash Flow Improvement?

Monash IVF Group (ASX:MVF) reported revenue of AUD 269.5 million for the year to 30 June 2026, down 0.9% year on year. Underlying EBITDA declined 19.5% to AUD 53.4 million, and underlying net profit after tax fell 41.2% to AUD 16.1 million. Reported net …

Aditi Sarkar | 02 November 2026

Paragon Care (ASX:PGC): What Do FY26 Revenue and Statutory Earnings Reveal?

Paragon Care (ASX:PGC) reported statutory revenue of AUD 3.7 billion for the year ended 30 June 2026, an increase of 1.8% year on year. Underlying EBITDA was AUD 97.2 million, an increase of 2.1%. However, statutory EBITDA declined 42.6% to AUD 50.8 million and …

Aditi Sarkar | 02 November 2026

Ramsay Health Care (ASX:RHC): How Could the Proposed Ramsay Santé Demerger Reshape Operations?

Ramsay Health Care (ASX:RHC) released its full-year results for the year ended 30 June 2026 on 27 August, followed by its 2026 annual report on 25 September. The group reports businesses in Australia, the United Kingdom and Europe, each facing different hospital operating conditions. …

Aditi Sarkar | 02 November 2026

Nanosonics Limited (ASX:NAN): What Do FY2026 Results Mean for CORIS Commercialisation?

For the year ended 30 June 2026, Nanosonics (ASX:NAN) reported revenue of AUD 203.9 million, an increase of approximately 3% year on year. At constant currency, revenue was AUD 211.5 million, reflecting exchange-rate effects on reported growth.Earningsbefore interest and tax were AUD 16.0 million, …

Aditi Sarkar | 02 November 2026

Healthcare

Healius Limited (ASX:HLS): What FY26 Pathology Earnings Reveal About Its Operating Priorities

PYC Therapeutics (ASX:PYC): Clinical Programmes, RNA Delivery and 2026 Milestones

PolyNovo (ASX:PNV): FY26 Revenue, NovoSorb Sales and Manufacturing Plans

Australian Clinical Labs (ASX:ACL): FY26 Pathology Revenue, Margins and FY27 Guidance

How Did Integral Diagnostics (ASX:IDX) Perform in FY26 After Its Imaging Network Expansion?

Telix Pharmaceuticals (ASX:TLX): What Do 2026 Revenue Growth and Pipeline Investment Show?

Why Did Monash IVF Group (ASX:MVF) Report Lower FY26 Earnings Despite Cash Flow Improvement?

Paragon Care (ASX:PGC): What Do FY26 Revenue and Statutory Earnings Reveal?

Ramsay Health Care (ASX:RHC): How Could the Proposed Ramsay Santé Demerger Reshape Operations?

Nanosonics Limited (ASX:NAN): What Do FY2026 Results Mean for CORIS Commercialisation?

Latest News

What a US fraud event means for Zip Co (ASX:ZIP) as the ASX 200 lender holds its FY27 guidance

How Xero (ASX:XRO) lifted its FY27 outlook after a Melio-driven first half

Why ASX 200 software group WiseTech Global Ltd (ASX:WTC) still faces scrutiny after ASIC closed its investigations

What the IMDA show cause notice means for Tuas Ltd (ASX:TUA) after a year of record revenue

Why Seek (ASX:SEK) Is Overhauling Its Growth Fund as the ASX 200 Jobs Marketplace Leans on Pricing

Why ASX 200 property portal REA Group (ASX:REA) is leaning on pricing as listings soften